SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Hits New 1-Year High – Time to Buy?

SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $70.66 and last traded at $70.42, with a volume of 8538 shares. The stock had previously closed at $69.80.

SPDR S&P Pharmaceuticals ETF Stock Performance

The firm’s 50-day moving average price is $64.28 and its two-hundred day moving average price is $59.18. The stock has a market cap of $504.86 million, a price-to-earnings ratio of 14.28 and a beta of 0.58.

Hedge Funds Weigh In On SPDR S&P Pharmaceuticals ETF

Several institutional investors and hedge funds have recently bought and sold shares of XPH. Bank of America Corp DE grew its stake in shares of SPDR S&P Pharmaceuticals ETF by 128.0% in the 1st quarter. Bank of America Corp DE now owns 811,939 shares of the company’s stock valued at $43,918,000 after buying an additional 455,802 shares during the period. Wells Fargo & Company MN lifted its holdings in SPDR S&P Pharmaceuticals ETF by 175.6% in the fourth quarter. Wells Fargo & Company MN now owns 207,229 shares of the company’s stock valued at $11,607,000 after acquiring an additional 132,037 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in SPDR S&P Pharmaceuticals ETF by 96.9% in the first quarter. Goldman Sachs Group Inc. now owns 119,929 shares of the company’s stock valued at $5,253,000 after acquiring an additional 59,007 shares during the last quarter. Private Advisor Group LLC purchased a new position in SPDR S&P Pharmaceuticals ETF in the first quarter worth approximately $3,017,000. Finally, BNP Paribas Financial Markets grew its position in SPDR S&P Pharmaceuticals ETF by 123.8% in the fourth quarter. BNP Paribas Financial Markets now owns 89,500 shares of the company’s stock worth $5,013,000 after acquiring an additional 49,500 shares during the period.

SPDR S&P Pharmaceuticals ETF Company Profile

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.